Catalyst Pharmaceuticals (NASDAQ:CPRX) Insider Carmen Jeffrey Del Sells 10,983 Shares

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) insider Carmen Jeffrey Del sold 10,983 shares of the stock in a transaction on Wednesday, November 26th. The stock was sold at an average price of $23.33, for a total transaction of $256,233.39. Following the transaction, the insider directly owned 3,962 shares in the company, valued at $92,433.46. The trade was a 73.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Catalyst Pharmaceuticals Stock Down 0.3%

Shares of NASDAQ:CPRX traded down $0.07 on Friday, reaching $23.36. The company had a trading volume of 527,443 shares, compared to its average volume of 1,358,908. Catalyst Pharmaceuticals, Inc. has a twelve month low of $19.05 and a twelve month high of $26.58. The stock has a 50-day moving average price of $21.30 and a 200 day moving average price of $21.73. The stock has a market capitalization of $2.87 billion, a P/E ratio of 14.16, a P/E/G ratio of 0.84 and a beta of 0.79.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last issued its quarterly earnings data on Monday, September 25th. The biopharmaceutical company reported $0.28 EPS for the quarter. Catalyst Pharmaceuticals had a return on equity of 40.78% and a net margin of 37.36%.The business had revenue of $53.11 million for the quarter. On average, sell-side analysts predict that Catalyst Pharmaceuticals, Inc. will post 1.9 earnings per share for the current fiscal year.

Catalyst Pharmaceuticals declared that its board has approved a share buyback plan on Wednesday, October 1st that permits the company to repurchase $200.00 million in outstanding shares. This repurchase authorization permits the biopharmaceutical company to reacquire up to 8.3% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s leadership believes its stock is undervalued.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

A number of hedge funds have recently made changes to their positions in CPRX. Huntington National Bank lifted its holdings in shares of Catalyst Pharmaceuticals by 105.0% during the 2nd quarter. Huntington National Bank now owns 1,433 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 734 shares during the period. Rothschild Investment LLC lifted its stake in Catalyst Pharmaceuticals by 1,085.7% during the third quarter. Rothschild Investment LLC now owns 1,660 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 1,520 shares during the period. Advisory Services Network LLC bought a new position in Catalyst Pharmaceuticals during the third quarter worth about $39,000. Quarry LP acquired a new stake in Catalyst Pharmaceuticals during the third quarter valued at approximately $40,000. Finally, Financial Life Planners bought a new stake in shares of Catalyst Pharmaceuticals in the 3rd quarter valued at approximately $42,000. Institutional investors and hedge funds own 79.22% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. Wall Street Zen raised shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Sunday, November 16th. Oppenheimer restated an “outperform” rating and set a $33.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday, November 7th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Catalyst Pharmaceuticals in a research report on Wednesday, October 8th. Citigroup boosted their price objective on Catalyst Pharmaceuticals from $31.00 to $33.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Finally, Zacks Research downgraded Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 19th. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, Catalyst Pharmaceuticals currently has an average rating of “Buy” and an average target price of $32.67.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.